Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Prognostic role of undetectable ablation thyroglobulin and follow-up thyroglobulin in patients with thyroid cancer

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 436–437 (2008)Cite this article

Phan HT et al. (2008) The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol 158: 77–83

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Cooper DS et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16: 109–142

    Article  Google Scholar 

  2. Pacini F et al. (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154: 787–803

    Article  CAS  Google Scholar 

  3. Chiovato L et al. (2003) Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139: 346–351

    Article  CAS  Google Scholar 

  4. Baudin E et al. (2003) Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88: 1107–1111

    Article  CAS  Google Scholar 

  5. Kim TY et al. (2005) Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90: 1440–1445

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Nuclear Medicine and Endocrine Tumor, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France leboulleux@igr.fr

Authors and Affiliations

  1. S Leboulleux is an Assistant Professor in the Department of Nuclear Medicine and Endocrine Tumor at the Institut Gustave Roussy, Villejuif, France.,

    Sophie Leboulleux

Authors
  1. Sophie Leboulleux
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leboulleux, S. Prognostic role of undetectable ablation thyroglobulin and follow-up thyroglobulin in patients with thyroid cancer. Nat Rev Endocrinol 4, 436–437 (2008). https://doi.org/10.1038/ncpendmet0864

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0864

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing